About us

2009year of creation
13research teams
385researchers & staff
4,200 m²of labs and facilities

Who we are

The Paris Cardiovascular Research Center (PARCC, UMR-S 970) is an interdisciplinary Université Paris Cité and Inserm research center located at the Hôpital Européen Georges Pompidou, bringing together basic scientists and clinician scientists who share a common vision. Our mission: understand and treat cardiovascular and renal diseases by linking their genetic and cellular mechanisms, the dialogue between organs, and observations from populations and patients.

On a single site, our teams combine molecular and cellular biology, integrative physiology, imaging, immunology, genetics and epidemiology to understand disease processes and develop new diagnostic and therapeutic strategies for vascular and cardiac diseases, hypertension, kidney diseases and transplantation.

Our history

2009
Term 1 · 2009–2013

Creation of PARCC

Inserm and Université Paris Descartes create the Paris Cardiovascular Research Center at the Hôpital Européen Georges Pompidou, with six teams and one Avenir team on a single 4,200 m² site. Under the direction of Alain Tedgui, this first term (2009–2013) lays the foundations of the center.

2010–2012

A growing center

Four new teams join PARCC, broadening its expertise in vascular biology, immunology and cardiology.

2014–2019
Term 2 · 2014–2019

13 research teams

The center is organised into 13 teams. New groups are created or join us, including Anne Eichmann’s team from the Collège de France, an Avenir team in organ transplantation (Alexandre Loupy) and Jean-Sébastien Hulot’s team. Term renewed following a successful HCERES / Inserm evaluation.

2019–2024
Term 3 · 2019–2024

12 research teams and a new director

PARCC brings together 12 research teams dedicated to cardiovascular diseases, led by Chantal Boulanger, Bertrand Tavitian, Nabila Bouatia-Naji, Xavier Jouven, Hafid Ait-Oufella, Jean-Sébastien Silvestre, Jean-Sébastien Hulot, Pierre-Louis Tharaux, Anne Eichmann, Éric Tartour, Judith Favier and Maria-Christina Zennaro. Chantal Boulanger succeeds Alain Tedgui as director. Term renewed following a successful HCERES / Inserm evaluation.

2020

Early career researchers

PARCC supports the creation of its early career researchers association, today known as the PARCCERs.

2021–2022

Structuring the Paris cardiovascular community

PARCC is a driving force in the creation of the Institute of Cardiovascular Sciences and the Graduate School Cardiovascular Sciences of Université Paris Cité.

2023

Transplantation, innovation and a new director

Launch of the Paris Institute for Transplantation & Organ Regeneration (PITOR), and arrival on site of Polygon Therapeutics, a start-up born from PARCC research. In October 2023, Jean-Sébastien Silvestre becomes director of PARCC, succeeding Chantal Boulanger.

2024

A new team in multi-organ dysfunction

Clément Cochain joins PARCC with an Inserm Junior Professor Chair (CPJ) and creates the team “Multi-organ dysfunction and cardiovascular pathology in metabolic diseases”.

2025–2030
Term 4 · 2025–2030

13 research teams for a new term

For the 2025–2030 term, PARCC is organised into 13 research teams, with the creation of Ivana Zlatanova’s ATIP-Avenir team on heart regeneration and David Smadja’s team on endotheliopathy and hemostasis. Jean-Sébastien Silvestre continues as director of PARCC. Term renewed following a successful HCERES / Inserm evaluation.

2025

Paris Institute for Global Health

Creation of the Paris Institute for Global Health of Université Paris Cité, in which PARCC teams are closely involved.

2026

Vision 2030 and new partnerships

PARCC defines a shared scientific identity around one continuum, heart · vessels · kidney, and three research axes, and signs a collaboration agreement with the OrganX Foundation.

Vision 2030: three research axes

Our research axes define a common scientific identity and guide our collaborations, investments and recruitments. Teams contribute to several axes, and joint programmes are co-led by at least two teams.

Axis 1

Genetic and molecular mechanisms

Which genetic determinants and cellular mechanisms produce disease, and where can we intervene?

From gene and cell to phenotype and intervention.

Axis 2

Immunometabolism and inter-organ dialogue

How do immune and metabolic interactions link organ damage and organ protection?

Immunometabolic circuits between organs.

Axis 3

From human cohorts to mechanisms and precision medicine

What do disease trajectories, risk and response to treatment reveal, and how can we explain them and intervene better?

From human signal to knowledge and decision.

Shared capabilities

Imaging, spatial and omics technologies, human and experimental models, biobanks and data science, supported by our technology platforms.

Directors of PARCC

Alain Tedgui2009 – 2018

Alain Tedgui

Founding director

Chantal Boulanger2019 – 2023

Chantal Boulanger

Former director

Jean-Sébastien SilvestreSince October 2023

Jean-Sébastien Silvestre

Current director

Our environment

Inserm & Université Paris Cité

PARCC is a joint research unit (UMR-S 970) of Inserm and Université Paris Cité, within its Faculty of Health.

Hôpital Européen Georges Pompidou

Located within the hospital (AP-HP), in close connection with its clinical departments and Clinical Investigation Center.

Institutes & Graduate School

PARCC teams are deeply involved in the Institute of Cardiovascular Sciences, PITOR, the Paris Institute for Global Health and the Graduate School Cardiovascular Sciences.

Polygon Therapeutics logo

Polygon Therapeutics

Immunotherapy of cardiovascular diseases.

Visit website →

OrganX logo

OrganX Foundation

A nonprofit health organization established to exponentially accelerate advances in organ technologies and patients’ access to organ health.

Visit website →

Detera Therapeutics logo

Detera Therapeutics

Disruptive therapies for rare kidney diseases.

Visit website →